BiotechTube

ENTR-601-44 + ENTR-601-44 - matching placebo

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy (DMD)

Conditions

Duchenne Muscular Dystrophy (DMD)

Trial Timeline

Jun 30, 2025 → Mar 28, 2029

NCT ID
NCT07037862

About ENTR-601-44 + ENTR-601-44 - matching placebo

ENTR-601-44 + ENTR-601-44 - matching placebo is a phase 1/2 stage product being developed by Entrada Therapeutics for Duchenne Muscular Dystrophy (DMD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07037862. Target conditions include Duchenne Muscular Dystrophy (DMD).

What happened to similar drugs?

2 of 20 similar drugs in Duchenne Muscular Dystrophy (DMD) were approved

Approved (2) Terminated (8) Active (11)
✅Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]Sarepta TherapeuticsApproved
✅vamorolone 40 mg/mL oral suspensionSanthera PharmaceuticalsApproved
❌Tadalafil + PlaceboEli LillyPhase 3
🔄Viltolarsen + PlaceboNippon ShinyakuPhase 3
🔄ViltolarsenNippon ShinyakuPhase 3
❌fordadistrogene movaparvovecPfizerPhase 3
🔄Ataluren + PlaceboPTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07037862Phase 1/2Recruiting

Competing Products

20 competing products in Duchenne Muscular Dystrophy (DMD)

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
29
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
29
Tadalafil + PlaceboEli LillyPhase 3
32
DS-5141bDaiichi SankyoPhase 2
39
DS-5141bDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
32
NS-065/NCNP-01Nippon ShinyakuPhase 2
35
Viltolarsen + PlaceboNippon ShinyakuPhase 3
40
ViltolarsenNippon ShinyakuPhase 2
35
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
39
NS-065/NCNP-01Nippon ShinyakuPhase 1
29
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
39
NS-089/NCNP-02Nippon ShinyakuPhase 2
42
ViltolarsenNippon ShinyakuPhase 3
36
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
32
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
35
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
27
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
27
SatralizumabRochePhase 2
42